Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

(2013) John P.H. Wilding   ANNALS OF INTERNAL MEDICINE

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

(2013) Serge A. Jabbour et al.   DIABETES CARE

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin

(2013) Sunder Mudaliar et al.   Diabetes Technology & Therapeutics

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin

(2012) Sreeneeranj Kasichayanula et al.   ADVANCES IN THERAPY

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

(2012) J. Rosenstock et al.   DIABETES CARE

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

(2012) Ö. Ljunggren et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range

(2012) C. J. Bailey et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

(2012) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

(2012) R. R. Henry et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

(2012) Jean Whaley et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

(2011) Scott C. Thomson et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study

(2011) Glenn F. Carlson et al.   Diabetes Therapy

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

(2010) S. Kasichayanula et al.   DIABETES OBESITY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Renal homeostasis and tubuloglomerular feedback

(2009) Prabhleen Singh et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

(2009) J. P.H. Wilding et al.   DIABETES CARE

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE